ReviewAmerican heart journal plus : cardiology research and practice2024
Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: A systematic review.
Review in American heart journal plus : cardiology research and practice, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 21 citations in OpenAlex.
- Clinical trials in a dish: cardiometabolic drug development with biological and digital twins.The Journal of clinical investigation · 2026Review
- Understanding the economic and healthcare burden of metabolic dysfunction-associated steatohepatitis: a real-world claims data analysis from Germany.Journal of comparative effectiveness research · 2026Article
- Sex differences in MASLD-related atherosclerosis: plaque phenotype, vascular dysfunction, and cardiovascular outcomes.Biology of sex differences · 2026Review
- Cardioprotective Effects of 1,3 Butanediol in MASLD via Reversal of Cardiac Lipid Accumulation and Suppression of Cardiac Fibrosis.International journal of molecular sciences · 2026Article
- Lower prolactin levels are associated with histological severity of metabolic dysfunction-associated steatotic liver disease.BMC endocrine disorders · 2026Article
- Hepatic Lipoprotein Production, Cardiometabolic Phenotypes, and Subtypes of Steatotic Liver Disease.Circulation research · 2026Review
- Overcoming the barriers in the screening, diagnosis, and follow-up of patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH).Reviews in endocrine & metabolic disorders · 2026Review
- Real-world quality of life and healthcare resource utilization in patients with metabolic dysfunction-associated steatohepatitis.JHEP reports : innovation in hepatology · 2026Article
- Influence of Metabolic Dysfunction-Associated Steatotic Liver Disease on Pattern and Management of Acute Coronary Syndrome.Saudi medical journal · 2026Article
- Ten-Year Atherosclerotic Cardiovascular Disease Risk in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Separate Analyses from Romanian and Italian Cohorts Integrating Metabolic, Hepatic, and Gut-Liver Axis Markers.Journal of clinical medicine · 2025Article
- Cardiac and liver impairment on multiorgan MRI and risk of major adverse cardiovascular and liver events.Nature medicine · 2025Article
- Evolving Role of GLP-1 Therapies in Liver Disease.Current gastroenterology reports · 2025Review
- Metabolic Dysfunction Associated-Steatotic Liver Disease (MASLD) and Cardiovascular Risk: Embrace All Facets of the Disease.Current cardiology reports · 2025Review
- Microbiome-mediated crosstalk between T2DM and MASLD: a translational review focused on function.Frontiers in endocrinology · 2025Review
- GLP-1, GIP/GLP-1, and GCGR/GLP-1 receptor agonists: Novel therapeutic agents for metabolic dysfunction-associated steatohepatitis.World journal of gastroenterology · 2024Review
- Kill two birds with one stone: Hapatologist's approach to metabolic dysfunction-associated steatotic liver disease and heart failure.World journal of cardiology · 2024Article
- Comparative Analysis of Resmetirom vs. FGF21 Analogs vs. GLP-1 Agonists in MASLD and MASH: Network Meta-Analysis of Clinical Trials.Biomedicines · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The burden of cardiovascular disease (CVD) in patients with metabolic dysfunction-associated steatohepatitis (MASH) is poorly characterized, particularly
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.